Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Stimulus Package Creates Flurry of Research Funds

Kurt Ullman  |  Issue: October 2009  |  October 1, 2009

“There wasn’t one single avenue for getting the money,” he says. “Some institutes took the money and looked at their backlog of unfunded projects. Some used administrative supplements to fund previously committed projects at higher levels. Many used a number of different approaches.”

There were at least two major challenges seen by researchers in the language of the ARRA. One was that all money had to be spent within two years. The second was a short deadline for submitting proposals.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Two-year Funding

“Most rigorously scientific projects will not fit well into a two-year time period,” noted Daniel Lovell, MD, professor of pediatrics at the Cincinnati Children’s Hospital Medical Center. “The upside is that it allowed researchers to focus on developing mechanisms and approaches that potentially could change the face of medical research if follow-up funding is available. They are building consortiums and capabilities to do longer term large studies.”

Dr. Carter acknowledges that this was a concern and limited the projects that could be funded. “In our experience, it is very hard to do any kind of real clinical trial within that timeframe,” he says. “Usually just getting all the things like study design, Institutional Review Board approval, and getting regulatory okays means 18 months pass before you can begin patient accrual. In the language of the RFA, we tried to make it clear we were discouraging clinical trials without some very compelling reason to think it could be completed quickly.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
Figure 1: NIH Allocations of ARRA Funds (in billions of dollars).
click for large version
Figure 1: NIH Allocations of ARRA Funds (in billions of dollars).

Large Numbers of Applicants

Despite the short timeline, the ARRA grants had no shortage of applicants. For example, one of the smaller funded mechanisms, the Challenge Grants, drew around 20,000 applications for $200 million in grants available throughout the NIH.

Michael Holers, MD, head of the division of rheumatology at the University of Colorado in Denver decided to not participate in the ARRA program. He summed up many of the problems voiced. “No one from this department, including me, decided to participate directly, and I suspect these decisions were based on many factors,” he says. “I think that the reasons would include the published scope of the ARRA grants, the time available to write a grant versus [time] needed for other commitments, the likelihood of a successful application with the anticipated number of funded proposals versus the expected number of submissions, other personal and professional commitments, and the availability of other grant sources to support a faculty member’s research that might have otherwise gone in the ARRA.”

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Legislation & AdvocacyProfessional TopicsResearch Rheum Tagged with:Basic researchClinical researchLegislationNational Institutes of HealthNIH

Related Articles

    National Institute of Arthritis & Musculoskeletal & Skin Diseases Report for 2015

    January 1, 2015

    NIAMS director Stephen I. Katz, MD, PhD, highlights agency research, training planned for this year and beyond

    Gorodenkoff / shutterstock.com

    The NIAMS Diversity Supplement Program Offers Researcher Funding

    January 10, 2022

    The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is a component of the National Institutes of Health (NIH) that supports research into the causes, treatment and prevention of arthritis and musculoskeletal and skin diseases, as well as the training of basic and clinical scientists to carry out this research. NIAMS recognizes the…

    NIAMS’ Intramural Research Programs Foster Spirit of Discovery

    March 1, 2015

    National Institute of Arthritis and Musculoskeletal and Skin Diseases program recognized for excellence in training, innovation

    Research Across the Spectrum

    September 1, 2009

    NIAMS director highlights innovative research initiatives

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences